Compare Ecolab Inc. (ECL) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Gilead Sciences, Inc. — how do they compare? Ecolab Inc. trades at $285 (market cap $79.79B), while Gilead Sciences, Inc. trades at $135.49 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 2.1× Ecolab Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| ECL | GILD | |
|---|---|---|
Market Cap | $79.79B | $168.35B |
Sector | Consumer Cyclical | Health |
52-Week High | $308.35 | $155.80 |
52-Week Low | $245.73 | $110.56 |
Enterprise Value | $88.57B | $191.42B |
Dividend Yield | 1.03% | 2.42% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
